Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safinamide safety study in Parkinson's disease
2008-005492-94Phase 3Completed
- Sponsor
- Merck Serono
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of safinamide in Parkinson's disease (PD), sponsored by Merck Serono. Primary endpoints: Change from baseline in physical examination findings, Change from baseline in neurological examination findings and 7 more. Started Apr 2009; status: completed.
02
Drugs
safinamide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2008-005492-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005492-94.